Tesamorelin news and clinical trials

A narrative review of 76 studies on peptide use in urology and sexual medicine found that while some agents like Bremelanotide and Tesamorelin have clinical backing, many others like CJC-1295 remain unvalidated and accessible only through unregulated markets.

A meta-analysis of four clinical trials involving 909 people with HIV found that tesamorelin reduced harmful abdominal visceral fat, waist circumference, and trunk fat while increasing lean body mass. The study noted the drug also led to modest improvements in cholesterol levels.

Researchers published the protocol for the TRIUMPH trial, which will examine the effect of tesamorelin combined with exercise in 100 sedentary older adults living with HIV. The study measures physical function, muscle quality, and biological endpoints at 24 and 48 weeks.

A review of peptides modulating the GH-IGF-1 axis highlights the significant gap between clinical evidence and unregulated self-administration protocols. Clinicians are advised to recognize potential adverse effects like endocrine disturbances, fluid retention, and metabolic issues.

Researchers published a pilot trial of 22 subjects comparing 10 weeks of 1 mg tesamorelin against placebo for cognition. While low-dose treatment was not directly linked with significant changes in measures, machine learning analysis identified potential brain changes.

A JBJS Reviews article summarizing injectable peptides in sports medicine concluded that these agents remain experimental, with clinical use limited to approved metabolic agents and rigorous research protocols due to uncertain safety and efficacy.

Columbia University posted results for a terminated study on tesamorelin for HIV lipodystrophy. The trial was stopped due to the lack of availability of the study drug after enrolling 6 participants.

Columbia University terminated its phase 4 trial evaluating tesamorelin in 6 patients with HIV lipodystrophy. The study was stopped because of a lack of availability of the study drug.

Case reports detailing two HIV patients with excess visceral abdominal fat suggested distinct therapeutic responses to tesamorelin and GLP-1 receptor agonists. The findings support individualized management strategies based on fat distribution rather than weight.

A study in rats found that calorie-dense diets combined with antiretroviral therapy induced cardiac damage, including myocardial fibrosis. Tesamorelin treatment prevented these deleterious electrocardiographic effects, suggesting it may counteract growth hormone pathway dysfunction.

Researchers published a review of approved and unapproved peptide therapies used in sports medicine. They found that while unapproved peptides often show potential for tissue repair in animal models, human safety data remain scarce and carry a risk of serious harm.

Hudson Biotech registered a phase 2 trial to evaluate whether daily subcutaneous tesamorelin reduces liver fat in 120 adults with metabolic associated steatotic liver disease. The study involves a 52-week treatment period.

University of California, San Diego posted results for a completed phase 2 trial testing tesamorelin for cognition in 73 aging HIV-infected persons. The study investigated the drug's effect on memory and thinking in combination with a text-messaging app.

A review of clinical research examined pharmacological treatments designed to preserve lean body mass during weight loss induced by obesity therapies like GLP-1 agonists. The authors identified bimagrumab, tesamorelin, and enobosarm as promising agents under investigation.

A meta-analysis of five randomized controlled trials found that tesamorelin significantly reduced visceral adipose tissue, trunk fat, and hepatic fat in HIV-associated lipodystrophy patients. It also increased lean body mass without serious side effects or glucose perturbation.

A review published in the Journal of the American Academy of Orthopaedic Surgeons analyzed the use of therapeutic peptides in orthopaedics. The authors noted that while peptides show promise in preclinical models for tissue regeneration, there is currently a lack of clinical trials.

A narrative review evaluated evidence for injectable peptide therapy in orthopaedic and sports medicine. The authors concluded that current clinical data remain limited or unvalidated for peptides like BPC 157 and others, necessitating further research before clinical use.

Massachusetts General Hospital posted results for a Phase 2 trial of tesamorelin in 51 obese individuals with non-alcoholic fatty liver disease. The study investigated whether the growth hormone releasing hormone analogue could decrease liver fat and improve inflammation and scarring.

Researchers developed and validated a nano-LC quadrupole/orbitrap mass spectrometry method to detect growth hormone-releasing hormone and analogs like sermorelin and CJC-1295 in urine. The method achieved limits of detection at or below 0.5 ng/mL, meeting WADA anti-doping testing requirements.